We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesUS Stem Cell Inc

US Stem Cell Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
60000
Market Cap
0.06M

Momentum Score

…

U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in November 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on US Stem Cell Inc (USRM.US), an OTC Pink–listed company, is limited; the company states it operates in regenerative medicine focusing on stem cell technologies and related products and services. Long-term growth may depend on scientific progress in regenerative therapies, successful product development or licensing, and wider clinical adoption, which could support revenue expansion and market interest.

Key risks include limited public disclosure and liquidity, regulatory and clinical development uncertainty, potential need for external financing, and competitive pressures in the regenerative medicine sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.08M
Revenue Per Share
-
Gross Profit TTM
0.06M
Debt / Equity
-0.61
ROE
-
Net Debt
8.94M
ROCE
12.28%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2.86M -3.84M -2.89M -3.84M -2.16M
Net income -3.31M -5.04M -2.89M -3.84M -2.16M
Selling general administrative 1.78M 2.28M 2.61M 4.45M 5.68M
Gross profit 0.06M 1.74M 0.21M 1.74M 4.59M
Reconciled depreciation - - 0.00M 0.24M 0.21M
Ebit -1.72M -3.42M -2.40M -2.72M -0.85M
Ebitda -1.72M -2.96M -2.40M -2.61M -0.64M
Depreciation and amortization 0.00M 0.46M - - 0.21M
Non operating income net other - - - - 0.38M
Operating income -1.72M -3.42M -2.40M -3.42M -1.10M
Other operating expenses 1.80M 6.49M - - 7.80M
Interest expense 0.69M 0.98M 0.49M 0.98M 1.44M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.69M -1.00M -0.49M -0.98M -1.44M
Income tax expense 0.45M 1.20M - - 1.06M
Total revenue 0.08M 3.07M 0.28M 3.07M 6.70M
Total operating expenses 1.78M 5.15M 2.68M 6.49M 5.69M
Cost of revenue 0.02M 1.34M 0.06M 1.34M 2.11M
Total other income expense net -1.14M -0.42M -0.00M 0.56M 0.38M
Net income from continuing ops -2.86M -3.29M -2.89M -3.84M -2.16M
Net income applicable to common shares -2.86M -3.29M -2.89M -3.84M -2.16M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 0.07M 0.09M 0.09M 0.09M 1.82M
Other current assets 0.06M 0.01M - - 0.04M
Total liab 14.81M 9.57M 11.67M 9.57M 8.70M
Total stockholder equity -14.75M -9.48M -11.58M -9.48M -6.88M
Deferred long term liab - - - - 0.09M
Other current liab 4.19M 2.09M 0.47M 0.51M 1.86M
Common stock 0.63M 0.42M 0.44M 0.42M 0.38M
Capital stock 0.63M 0.50M 0.44M 0.42M 0.38M
Retained earnings -142.52M -133.62M -136.51M -133.62M -129.79M
Other liab 0.05M 0.06M 0.06M 0.06M 0.19M
Other assets - - - - 0.01M
Cash 0.01M 0.02M 0.02M - 1.36M
Total current liabilities 14.08M 8.75M 10.85M 8.75M 5.92M
Current deferred revenue 0.00M 0.05M - - 0.42M
Net debt 8.94M 6.18M 7.47M 6.18M 3.69M
Short term debt 8.26M 5.42M - - 2.46M
Short long term debt 8.26M 7.29M 6.72M 5.42M 2.46M
Short long term debt total 8.95M 6.18M - - 5.05M
Other stockholder equity 127.14M 123.73M - - 122.53M
Property plant equipment - - - - 0.24M
Total current assets 0.07M 0.07M 0.09M 0.07M 1.51M
Long term investments - - - 0.02M 0.06M
Net tangible assets -14.75M -12.77M -11.58M -9.48M -6.88M
Net receivables 0.00M 0.05M 0.05M 0.05M 0.02M
Long term debt 0.68M 0.72M 0.76M 0.76M 2.60M
Inventory 0.00M 0.01M 0.01M 0.01M 0.09M
Accounts payable 1.62M 1.19M 1.28M 1.19M 1.18M
Common stock total equity - - - - 0.38M
Retained earnings total equity - - - - -129.79M
Non currrent assets other - - - - 0.01M
Non current assets total 0.00M 0.02M 0.00M 0.02M 0.31M
Long term debt total - - - - 2.60M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - 0.00M 0.17M 0.31M
Change to liabilities 0.27M 0.07M 0.13M 0.07M 0.73M
Total cashflows from investing activities - - - 0.17M 0.31M
Net borrowings 0.19M 0.80M 0.50M -0.36M -1.01M
Total cash from financing activities 0.27M -0.31M 0.50M -0.31M -0.54M
Change to operating activities 0.02M -0.01M 0.02M 0.02M 0.19M
Net income -2.86M -3.84M -2.89M -3.84M -2.16M
Change in cash -0.03M -1.36M 0.02M -1.36M 0.37M
Begin period cash flow 0.04M 1.36M 0.00M 1.36M 0.99M
End period cash flow 0.01M 0.02M 0.02M 0.00M 1.36M
Total cash from operating activities -0.30M -1.21M -0.48M -1.21M 0.60M
Issuance of capital stock 0.09M 0.28M 0.00M 0.05M 0.37M
Depreciation 0.69M 0.24M 0.00M 0.24M 0.21M
Change to inventory -0.00M 0.09M 0.00M 0.09M -0.02M
Change to account receivables -0.00M -0.08M -0.01M -0.08M -0.04M
Sale purchase of stock - - - - 0.37M
Other cashflows from financing activities 0.21M 0.47M - - 0.45M
Change to netincome 2.27M 2.20M 2.27M 2.09M 0.92M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - - - -0.04M
Cash flows other operating - - - - 0.77M
Cash and cash equivalents changes - - - - 0.37M
Change in working capital 0.29M 0.10M 0.14M 0.10M 0.64M
Stock based compensation 0.38M 0.82M 0.70M 0.82M 1.23M
Other non cash items 1.20M 1.88M 1.57M 1.88M 1.01M
Free cash flow -0.30M -1.21M -0.48M -1.21M 0.60M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
USRM
US Stem Cell Inc		 -
-%		 0.00 - - 0.78 - 109.76 -6.33
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

US Stem Cell Inc

U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in November 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

1560 Sawgrass Corporate Parkway, Sunrise, FL, United States, 33323

954 835 1500

https://us-stemcell.com

Name Title Year Born
Mr. Michael Tomas CEO, Pres, CFO & Director 1966
Dr. Colleen Robb Sr. Compliance Officer NA
Mr. Phil Posa Sr. VP of U.S. & International Sales NA
Ms. Evelyn Flores Corp. Controller NA
Dr. Sergio Pinski Medical Director & Member of Scientific Advisory Board NA
Mr. James L. Greene Clinical Operations Consultant NA
Fabianne Gershon Consultant NA
Mr. Michael Tomas CEO, President, CFO & Director 1966
Ms. Evelyn Flores Corporate Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…